Antibodies to olanzapine haptens and use thereof

1. An immunoassay method for detecting an analyte comprising:

(i) generating an antibody or a binding fragment thereof in response to a conjugate of a compound of Formula I and an immunogenic carrier,

wherein:

R 1 is

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) 2 CO 2 H;

R 2 is H;

R 3 is H;

wherein:

m is 1 or 5; and

wherein the conjugate of the compound of Formula I and the immunogenic carrier is formed by attaching the immunogenic carrier to the substituent at the R 1 position of Formula I;

(ii) contacting a sample with the antibody or binding fragment thereof labeled with a detectable marker, wherein the labeled antibody or binding fragment and the analyte present in the sample form a labeled complex; and

(iii) detecting the labeled complex so as to detect the analyte in the sample.

2. A competitive immunoassay method for detecting an analyte comprising:

(i) generating an antibody or a binding fragment thereof in response to a conjugate of a compound of Formula I and an immunogenic carrier,

wherein:

R 1 is

CH 2 NH 2 , or CH 2 NHC(O)(CH 2 ) 2 CO 2 H;

R 2 is H;

R 3 is H;

wherein:

m is 1 or 5; and

wherein the conjugate of the compound of Formula I and the immunogenic carrier is formed by attaching the immunogenic carrier to the substituent at the R 1 position of Formula I;

(ii) attaching to a solid support (a) the antibody or binding fragment thereof, or (b) the analyte or a competitive binding partner of the analyte;

(iii) passing a sample and a labeled component through the solid support, wherein the labeled component is (a) the analyte or the competitive binding partner of the analyte attached to a detectable marker, when the antibody or binding fragment thereof is attached to the solid support, or (b) the antibody or binding fragment thereof attached to the detectable marker, when the analyte or a competitive binding partner of the analyte is attached to the solid support; and

(iv) detecting the detectable marker.

3. The method of claim 2 , wherein the analyte or competitive binding partner thereof is labeled with the detectable marker.

4. The method of claim 2 , wherein the antibody is labeled with the detectable marker.

5. The method of claim 2 , wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.

6. The method of claim 1 , wherein the sample is a biologic sample from a patient and the method further comprises determining attainment of minimum pK levels of the analyte in the subject.

7. The method of claim 1 , wherein the method further comprises determining bioequivalence of the analyte in multiple formulations or from multiple sources based on the detection of the analyte.

8. The method of claim 1 , wherein the method further comprises including or excluding a patient into a clinical trial based on the detection of the analyte.

9. The method of claim 2 , wherein the sample is a biologic sample from a subject and the method further comprises determining the attainment of minimum pK levels of the analyte in the subject.

10. The method of claim 2 , wherein the method further comprises determining bioequivalence of the analyte in multiple formulations or from multiple sources based on detecting the presence of the analyte.

11. The method of claim 2 , wherein the method further comprises including or excluding a patient in a clinical trial based on detecting the presence of the analyte.

12. The method of claim 1 , wherein the conjugate of a compound of Formula I and the immunogenic carrier has the following structure:

13. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

14. The method of claim 2 , wherein the conjugate of a compound of Formula I and the immunogenic carrier has the following structure:

15. The method of claim 2 , wherein the compound of Formula I is selected from the group consisting of: